Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide

Table 2

Treatment characteristics and clinical outcomes.

Characteristic	Whole cohort; ()	L-PIV; ()	H-PIV; ()	value
Adjuvant TMZ cycles, (%)
1-6	84 (41.2)	33 (44.0)	51 (39.5)	0.32
7-12	120 (58.8)	42 (56.0)	78 (60.5)
Brain failure, (%)
Absent	14 (6.9)	12 (16.0)	2 (1.6)	0.02
Present	190 (93.1)	63 (84.0)	127 (98.4)
Brain failure type, (%)
None	14 (6.9)	12 (16.0)	2 (1.6)	0.19
Infield	164 (80.4)	56 (74.6)	108 (83.7)
Marginal	16 (7.7)	5 (6.7)	11 (8.5)
Distant	4 (1.9)	0 (0)	4 (3.1)
Infield and distant	5 (2.6)	2 (2.7)	3 (2.3)
Marginal and distant	1 (0.5)	0 (0)	1 (0.8)
Salvage treatment, (%)
Absent	71 (34.8)	27 (36.0)	44 (34.1)	0.91
Present	133 (65.2)	48 (64.0)	85 (65.9)
Salvage treatment, (%)
None	71 (34.8)	27 (36.0)	44 (34.1)	0.57
BEVIRI	38 (18.7)	14 (18.7)	24 (18.6)
RO	17 (8.3)	7 (9.3)	10 (7.8)
SRS/SRT	17 (8.3)	6 (8.0)	11 (8.5)
/SRT	16 (7.8)	6 (8.0)	10 (7.8)
	19 (9.4)	6 (8.0)	13 (10.0)
	17 (8.3)	6 (8.0)	11 (8.5)
Unknown	9 (4.4)	3 (4.0)	6 (4.7)
Progression-free survival
Median, mo. (95% CI)	10.3 (7.8-131)	17.4 (13.3-21.4)	7.3 (5.3-9.3)	<0.001
1-year, %	48.2	69.0	36.0	0.007
3-year, %	10.8	25.6	2.4	<0.001
5-year, %	6.4	18.0	0	<0.001
Overall survival
Median, mo. (95% CI)	15.8 (13.0-18.6)	24.9 (22.0-27.8)	12.4 (10.5-14.2)	<0.001
1-year, %	63.9	82.5	53.1	0.003
3- year, %	11.8	25.6	4.2	<0.001
5-year, %	7.3	20.8	0	<0.001

Abbreviations: L-PIV: low pan-immune-inflammation value; H-PIV: high pan-immune-inflammation value; TMZ: temozolomide; BEVIRI: bevacizumab plus irinotecan; RO: reoperation; SRS/SRT: stereotactic radiosurgery/stereotactic radiotherapy.